Hair Loss treatments, a need to be considered space

Announcement

The new generation of companies has been keeping an eye on the niche-sized hair loss market with fingers crossed for the best new scientific focus and formulations to discover treatments not only effective and safe, but also excelling commercially. The progress of the GLP-1 weight loss treatments grabbed the attention of many, along with Lilly’s tirzepatide franchise transcended Merck’s spectacular Keytruda in three years after its clearance for type 2 diabetes and two years after the FDA signalled the obesity treatment Zepbound.

Apart from Lilly, Novo Nordisk’s sister medicine Ozempic and Wegovy also stand strong in the market, predicting $100 billion profit in the coming year. Overall, this potential has proved that nothing is impossible when it comes to thriving in an impossible scenario; the hair loss market hopes the same potential to enlighten the market.

Hair loss in line, expecting a first-in-class treatment from the healthcare potential

After GLP-1, the question arises as to what type of treatment could retain this feat? The predictable candidates are optional mechanisms for obesity. Still, the other drug development niches have recently opened up to the biopharma behind the scenes, rolling in extreme cash in financing rounds featuring hair loss treatments.

The CEO of Veradermics, Reid Waldman, said, “Hair loss is a severe, high-prevalence condition with almost 80 million individuals in the US alone. One individual proactively attempted to treat 15 million consuming a drug. Despite that, there’s no new male approval in these 30 years for an oral treatment. There was never any approval for an oral for females. Hence, there’s a vast space for opportunities to drive in here.”

Last month, the Veradermics and Pelage Pharmaceuticals stated that they convinced investors, making them believe in the capability of their hair loss treatments, with $150 million and $120 million in financing secured, to improve these assets. Alongside, there were breakthroughs spotted in immune-related hair loss, like alopecia areata. There are some treatment alternatives for androgenetic alopecia, involving pattern hair loss. It’s a general root cause found in both women and men.

As of now, Veradermics and Pelage are alone in this area; AbbVie is under testing of its excellent therapy Rinvoq, currently in phase 3 trials for alopecia areata. Whereas Stemson Therapeutics is establishing autologous cell therapies to generate new hair follicles for hair restoration permanently, and Amplifica is targeting signalling molecules that elevate hair follicle regeneration to cure androgenic alopecia.